MANILA, Philippines — After her daunting testimony, it has been almost two days since Pharmally Pharmaceutical Corp. executive Krizle Grace Mago last made contact with the Senate Blue Ribbon Committee.
According to Sen. Richard Gordon, the Senate Blue Ribbon Committee offered protection for Mago and asked for her exact address and location at 5:47 p.m Friday, Sept. 24.
Mago said that she will get back to the committee after the hearing, at 7:27 p.m. later that day.
The committee then followed up on Mago’s location and contacted her again in the morning of Sunday, Sept. 26 at 8:15 a.m.
They then tried calling her at 9:13 a.m. but she and her number can no longer be reached.
At 2:39 p.m. on Sunday Gordon on Twitter reiterated the committee’s concern for the safety of Mago.
“We are concerned for her safety after what she confirmed to us during last Friday’s hearing. We offered her protection. After attempts to get her exact location so we could send our Senate Sergeant-at-Arms, she can no longer be reached.
We are concerned for her safety after what she confirmed to us during last Friday’s hearing. We offered her protection. After attempts to get her exact location so we could send our Senate Sergeant-at-Arms, she can no longer be reached. pic.twitter.com/GBJuJHCsck
— Richard J. Gordon (@DickGordonDG) September 26, 2021
In Inquirer.net’s last message with the Senator, Gordon said the whereabouts of Mago has still not yet been identified as of 3:53 p.m. Sunday. It is still unknown whether or not she is safe.
READ: Mago ‘incommunicado’ since damning testimony vs Pharmally
Senate President Vicente Sotto III earlier instructed the Senate’s Office of the Sergeant-at-Arms to look for Mago.
READ: Senators want Pharmally employee placed under protective custody
During the ninth hearing of Gordon’s committee on Friday, Mago confessed that she ordered the company’s warehouse workers to change the 2020 production date to 2021 in the certification documents of the face shields to make it appear that they were produced only this year.
Pharmally is at the center of the blue ribbon committee’s investigation of the allegedly irregular transfer of at least P42 billion in pandemic funds from the DOH to the PS-DBM, which negotiated contracts for medical supplies with Pharmally and other companies.
Pharmally, however, only had a paid-up capital of P625,000 but managed to bag P11.7 billion worth of contracts with the Procurement Service of the Department of Budget and Management (PS-DBM) to supply the Department of Health (DOH) with face masks and shields, personal protective equipment (PPE) and COVID-19 testing kits.
RELATED STORY
Pharmally supplier pays additional taxes amid Senate probe